Welcome to our dedicated page for Quanome Technologies SEC filings (Ticker: QNME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quanome Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quanome Technologies's regulatory disclosures and financial reporting.
Quanome Technologies, Inc. (QNME) filed a pre‑effective amendment to a Form S‑3 shelf registration to offer and sell up to $120,000,000 of common stock, preferred stock, debt securities, warrants, rights and units from time to time, subject to a prospectus supplement for each takedown.
The company’s common stock trades on Nasdaq under “QNME”; the closing price was $0.3302 on September 1, 2026. As of September 2, 2026, public float was about $23.9 million, triggering the Baby Shelf Limitation that caps primary offerings to one‑third of float in any 12‑month period while float remains below $75 million.
Quanome is a Nevada holding company; substantially all current revenue comes from PRC pharmaceutical distribution through wholly owned subsidiary Hupan Pharmaceutical. The filing details extensive PRC legal, regulatory, cash‑transfer, CSRC filing and cybersecurity risks, HFCAA‑related audit risks, and notes Nasdaq minimum bid‑price deficiency and potential reverse split. The company has funded PRC subsidiaries with approximately $12.7 million and has paid no dividends.
Quanome Technologies, Inc. (QNME) announced the establishment of a Global Quantum Council and a complementary Scientific Advisory Network to deepen its understanding of quantum science, advanced technologies and their potential applications across industries and society.
The Global Quantum Council is being organized around four specialist streams, each drawing on targeted scientific and technical expertise. Together with the broader Scientific Advisory Network, these independent advisory forums are intended to provide perspective, support scientific evaluation, and help identify technologies, research initiatives, projects and applications that may merit collaboration, partnership or potential investment, particularly in fields such as healthcare, pharmaceutical discovery, advanced materials, energy, cybersecurity, financial services and industrial technologies.